Tuesday, May 16 2023
08:20 AM – 08:40 AM PT
TCR based strategies: State of the Art and Future Directions
Aude Chapuis, MD. Fred Hutchinson Cancer Research Center, Seattle, WA
Disclosures: A. Chapuis: 1; Commercial Interest i.e. Company X; Adaptive Biotechnologies Corporation. 1; For what role? i.e. Speaker; Partnership, Patent. 2; Commercial Interest i.e. Company X; Affini-T. 2; What was received? i.e. Honorarium; Compensation. 2; For what role? i.e. Speaker; Founder, Scientific Advisory Board, Patent. 3; Commercial Interest i.e. Company X; BioNTech. 3; What was received? i.e. Honorarium; Compensation. 3; For what role? i.e. Speaker; Consulting. 4; Commercial Interest i.e. Company X; Metagenomi. 4; What was received? i.e. Honorarium; Investments. 4; For what role? i.e. Speaker; Partnership, Scientific Advisory Board. 5; Commercial Interest i.e. Company X; SignalOne Bio. 5; What was received? i.e. Honorarium; Compensation. 5; For what role? i.e. Speaker; Partnership, Scientific Advisory Board. 6; Commercial Interest i.e. Company X; TScan Therapeutics. 6; What was received? i.e. Honorarium; Compensation. 6; For what role? i.e. Speaker; Partnership, Scientific Advisory Board. 7; Commercial Interest i.e. Company X; Amazon.com. 7; For what role? i.e. Speaker; Patent. 8; Commercial Interest i.e. Company X; Celegene. 8; For what role? i.e. Speaker; Patent. 9; Commercial Interest i.e. Company X; Cullinan, ElevateBio, Lonza Walkersville Inc.. 9; For what role? i.e. Speaker; Patent.